CGTX
NASDAQCognition Therapeutics Inc.
Price$1.22-0.04 (-3.57%)
01:30 PM07:45 PM
News · 26 weeks40-60%
2025-12-142026-06-07
Mix2290d
- SEC Filings9(41%)
- Other5(23%)
- Earnings4(18%)
- Insider4(18%)
Latest news
25 items- SECCognition Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
- PRCognition Therapeutics Participating in Upcoming Investor ConferencesPURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company's plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition's website. Event: 2026 Jefferies Global Healthcare Conference Date/Time: June 4, 2026 at 1:25 p.m. Eastern TimeWebcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/
- SECCognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
- PRCognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), conducted a planned meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026. The objective of this meeting was to review results from the Phase 2 study of zervimesine (CT1812) and discuss the design and endpoints of a registrational study in dementia with Lewy bodies (DLB) patients with psychosis. Lisa Ricciardi, president and CEO of Cognition, stated, "Yester
- PRCognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesPURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a second philanthropic donation has been received from a participant in the ongoing expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a generous new donation from Mr. Jeffrey Pechter, founding partner of Mindful Capital in Delray Beach, FL. The open-label EAP (COG1202) was launched in 2025 with funding by a generous donation from the family of a DL
- SECSEC Form 10-Q filed by Cognition Therapeutics Inc.10-Q - COGNITION THERAPEUTICS INC (0001455365) (Filer)
- SECCognition Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
- PRCognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business UpdateMeeting with FDA Division of Psychiatry scheduled for May 2026 expected to informregistrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the first quarter ended March 31, 2026, and provided a business update. "We filed a request to meet with the Food and Drug Administration's Division of Psychiatry to discuss our plans for a registrational study in people with dementia with Lewy body (DLB) psychosis," stated Lisa Ricciardi, Cognition's pre
- INSIDERChief Financial Officer Doyle John Brendan covered exercise/tax liability with 8,567 shares, decreasing direct ownership by 1% to 618,942 units (SEC Form 4) (for tax liability)4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
- SECSEC Form DEFA14A filed by Cognition Therapeutics Inc.DEFA14A - COGNITION THERAPEUTICS INC (0001455365) (Filer)
- SECSEC Form DEF 14A filed by Cognition Therapeutics Inc.DEF 14A - COGNITION THERAPEUTICS INC (0001455365) (Filer)
- INSIDERSEC Form 4 filed by Doyle John Brendan4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
- INSIDERSEC Form 4 filed by Ricciardi Lisa4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
- INSIDERSEC Form 4 filed by Caggiano Anthony4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
- PRCognition Therapeutics to Present at Needham Virtual Healthcare ConferencePURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13th at 3:00 p.m. Eastern Time. During her presentation, Ms. Ricciardi will provide an update on progress of the Company's development programs for Alzheimer's disease and dementia with Lewy bodies (DLB). A live webcast of Ms. Ricciardi's presentation will be available on the Investor Relations section of Cognition's website or by visiting: https://event.summitc
- PRCognition Therapeutics CEO Issues Letter to ShareholdersAdvancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders, has published CEO Lisa Ricciardi's Letter to Shareholders. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER To my fellow Shareholders, We made significant progress in 2025 towards our goal of developing transformative treatments for neurodegenerative diseases. As discussed on our
- SECSEC Form S-8 filed by Cognition Therapeutics Inc.S-8 - COGNITION THERAPEUTICS INC (0001455365) (Filer)
- SECSEC Form 10-K filed by Cognition Therapeutics Inc.10-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
- SECCognition Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
- PRCognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy
- PRCognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial ResultsPURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open. Management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference Call InformationTo participate in the conference call, dial (800) 445-7795 (U.S.) or (785) 424-1699 (international) and provide conference ID number CGTXQ4. The webc
- PRCognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Zervimesine's treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB. "In the Phase 2 ‘SHIMMER' study, we saw a treatment effect across neuropsychia
- SECCognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
- PRCognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) PsychosisPURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026. "Based on the Agency's meeting minutes and the strength of our Phase 2 ‘SHIMMER' data in the psychiatric and behavioral domain, we believe the best strategy is to pursue a
- INSIDERCEO & President Ricciardi Lisa covered exercise/tax liability with 5,850 shares, decreasing direct ownership by 0.34% to 1,706,676 units (SEC Form 4)4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
CGTX FAQ
7 questionsWhat does Cognition Therapeutics Inc. do?
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular...Where does CGTX stock trade?
Cognition Therapeutics Inc. (CGTX) is listed on NASDAQ.What sector and industry is CGTX in?
Cognition Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Cognition Therapeutics Inc. go public?
Cognition Therapeutics Inc. (CGTX) completed its IPO in 2021.What are analysts saying about CGTX?
Cognition Therapeutics Inc. has had 4 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $150.00 price target on 2024-12-19.What companies are similar to CGTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CGTX side-by-side with any of them on Quantisnow.How can I track CGTX on Quantisnow?
Quantisnow aggregates Cognition Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CGTX to receive live email and push alerts on every new disclosure.